Infliximab vs. Adalimumab in Crohn's Disease Infliximab vs. Adalimumab in Crohn's Disease
Do the anti-TNF agents infliximab and adalimumab have comparable response characteristics? Are concomitant immunomodulators necessary for optimal response?Alimentary Pharmacology & Therapeutics (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 28, 2017 Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news

Report finds pharma companies limited January list price hikes
Drug-makers didn’t raise list prices for as many drugs in January compared to last year and they initiated fewer hikes of 10% or more, according to analysis by Raymond James & Associates. Although 5.5% of price increases reached the 10% level in January this year, 15% did last year and 20% did 2 years ago. However, the median drug-price increase held steady compared to last year at 8.9% – far exceeding the U.S. inflation rate of 2%. Price increases held below 10% can still drive up total drug spending by hundreds of millions of dollars, according to the Wall Street Journal. AbbVie (NYSE:ABBV) raised the lis...
Source: Mass Device - February 27, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Healthcare Reform Pharma Pharmaceuticals Wall Street Beat AbbVie Allergan Inc. Johnson & Johnson Marathon Pharmaceuticals Merck Novo Nordisk Source Type: news

Remicade vs. Humira
Title: Remicade vs. HumiraCategory: MedicationsCreated: 2/27/2017 12:00:00 AMLast Editorial Review: 2/27/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 27, 2017 Category: Drugs & Pharmacology Source Type: news

Baricitinib Might Offer Oral Alternative to Adalimumab in RA Baricitinib Might Offer Oral Alternative to Adalimumab in RA
A phase 3 trial in patients with rheumatoid arthritis who did not respond to methotrexate showed that the addition of baricitinib produced significant clinical improvements.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

New non-steroid treatment for uveitis
Treatment TermsUveitis CategoriesAdvanced treatmentsClinical trials Additional SEO Keywords uveitis, Humira SEO Meta Description A clinical trial at Duke for a drug approved by the FDA to treat uveitis helped Shirley Mims see clearly again. Author Karen Doss Bowman Overview Shirley Mims thought she would go blind when she was first diagnosed with uveitis. A clinical trial at Duke for a drug now approved by the FDA to treat uveitis helped her see clearly again. Hero Imagestory_181716_jaffe047.jpg Preview Image Content Blocks Header Suddenly seeing spots ContentShirley Mims was driving home from...
Source: dukehealth.org: Duke Health News - February 20, 2017 Category: Consumer Health News Authors: dg62 at duke.edu Source Type: news

Baricitinib Scores High in Phase III (CME/CE)
(MedPage Today) -- Superior to adalimumab for clinical and functional outcomes (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 15, 2017 Category: Geriatrics Source Type: news

Adalimumab Effective in Crohn's Disease With Strictures Adalimumab Effective in Crohn's Disease With Strictures
The TNF inhibitor works well for patients with Crohn ' s disease accompanied by symptomatic strictures; disease control was well maintained in those who respond through nearly 4 years of follow-up.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 6, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Amgen Gets EMA Ok for Humira Biosims
The European Medicines Agency (EMA) recommended the approval of two Amgen biosimilars for AbbVie ’s blockbuster Humira, for treatment of inflammatory diseases. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 28, 2017 Category: Pharmaceuticals Source Type: news

Arthritis Drugs Get Nod From EMA's CHMP Arthritis Drugs Get Nod From EMA's CHMP
Tofacitinib citrate (Xeljanz), two adalimumab (Humira) biosimilars, and one methotrexate hybrid get thumbs up from EMA committee.International Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - January 27, 2017 Category: Dermatology Tags: Rheumatology News Alert Source Type: news

Psoriasis and Arthritis Drugs Get Nod From EMA's CHMP Psoriasis and Arthritis Drugs Get Nod From EMA's CHMP
Tofacitinib citrate (Xeljanz), two adalimumab (Humira) biosimilars, and one methotrexate hybrid get thumbs up from EMA committee.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 27, 2017 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
First Adalimumab Biosimilar Candidate Recommended for EMA Approval THOUSAND OAKS, Calif., Jan. 27, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 501 (biosimilar adalimumab), recommending approval for all available indications. ABP 501 has been recommended for approval for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis (AS), se...
Source: Amgen News Release - January 27, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Boehringer Ingelheim biosimilar candidate to Humira ® accepted for EMA and FDA regulatory review
Boehringer Ingelheim announced that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA). (Source: World Pharma News)
Source: World Pharma News - January 19, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Guselkumab Beats Adalimumab for Moderate to Severe Psoriasis Guselkumab Beats Adalimumab for Moderate to Severe Psoriasis
Guselkumab is effective for treating patients with moderate to severe psoriasis, according to results from Janssen ' s VOYAGE 1 and VOYAGE 2 trials.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 17, 2017 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

Boehringer Ingelheim biosimilar candidate to Humira < sup > ® < /sup > accepted for EMA and FDA regulatory review
Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 17, 2017 Category: Research Source Type: news

Pfizer reports positive top-line data from REFLECTIONS B538-02 study of PF-06410293
Pfizer has reported positive top-line data from its REFLECTIONS B538-02 study of PF-06410293 compared with Humira to treat moderate-to-severe rheumatoid arthritis (RA). (Source: Drug Development Technology)
Source: Drug Development Technology - January 9, 2017 Category: Pharmaceuticals Source Type: news